Bio-Tissue, Inc. was founded in 1997 to help address unmet needs for improved surgical and therapeutic alternative to treat ocular surface conditions; one that would serve as a non-immunogenic tissue replacement and would help facilitate tissue regeneration. Initial research began in the 1980s, led by Scheffer C.G. Tseng, MD, PhD, who believed the solution was to utilize the natural properties of human amniotic membrane tissue to restore ocular surface health. In 1995, Dr. Tseng reintroduced the use of amniotic membrane for ocular surface reconstruction, by utilizing a unique method of processing and preservation – the CryoTek® Method. Today, the company’s products are used by eye care professionals around the world.
Bio-Tissue, Inc. develops innovative wound care and ocular hygiene solutions for ocular surface diseases and disorders. Bio-Tissue provides a comprehensive line of cryopreserved amniotic membrane products, including AmnioGraft®, a biologic ocular transplantation graft; AmnioGuard®, a biologic glaucoma shunt tube graft; and the PROKERA® family of biologic corneal bandage devices.
These products incorporate human amniotic membrane and umbilical cord processed with the Company’s proprietary CryoTek cryopreservation method. This ensures the tissue retains its natural biologic properties that help manage inflammation, reduce scarring and wound healing.
Bio-Tissue also develops and markets Cliradex®, a natural lid, lash and facial cleanser with that only contains 4-Terpineol, the most important component of tea tree oil (TTO), for the management of symptoms of lid margin diseases such as blepharitis, demodex, and rosacea.
Bio-Tissue is a leader in the ophthalmic industry with over 30 years of clinical history, 360 peer-reviewed publications, and over 500,000 successful human transplantations.
BioTissue's Vision, Mission and Values
Vision:
Our vision is to empower healthcare professionals to deliver optimal patient healing outcomes, setting the standards that define regenerative medicine. Our Mission
Solving unmet clinical needs as the PATIENT-FOCUSED PIONEER of birth-tissue regenerative medicine; fostering TRUST as the EVIDENCE-BASED MARKET LEADER in ocular, surgical wound, and pain management markets; and providing DIFFERENTIATED, customer-recognizable, and sustainable HEALTH ECONOMIC VALUE.
In the coming 5 years, we envision that Bio-Tissue will be the leader in the regenerative biologics, based on our superior platform technology, our constant scientific research and discoveries, and our commitment to continuously build the commercial infrastructure to effectively deliver these innovations to the patients that need them. Over 30 years ago, we entered into ophthalmology as the first company in the medical community to introduce the utilization of amniotic membrane and umbilical cord as regenerative biomaterials, preserving their anti-inflammatory, anti-scarring and promoting growth properties with our proprietary CryoTek® Method. Today, the medical community has accepted our technology as the standard of care in treating many diseases. As we market heats up and competition increases, we plan to stay ahead of the curve by expanding our clinical uses and overcoming regulatory and reimbursement barriers. We believe Bio-Tissue is well established and set up to become the leader within this industry.
Based on our edge in scientific and clinical knowledge and our commitment to invest in our technology, Bio-Tissue continues to be at the forefront of this evolving industry over the coming years.
Our scientists discovered the abundant biological properties in human amniotic membrane and umbilical cord tissue that can promote regenerative healing. It is our mission to deliver the therapeutic benefits of this tissue by developing innovative and high-quality products for multiple disease indications to help address unmet patient needs and improve patient outcomes.
